



Immuron CEO Presents at 2014 Bioshares Biotech Summit

Melbourne, Australia - 21 July 2014: Australian biopharmaceutical company Immuron Limited (ASX: IMC) presented at a prestigious Bioshares Biotech Summit in Queenstown, New Zealand on the afternoon of Friday 18th July 2014.

The 10th Annual Bioshares Biotech Summit is hosted by Australia's leading independent biotech investment publication Bioshares. The summit joins life science companies from Australia and New Zealand with private and institutional investors from Australasia and the US. It is aptly described as an 'essential biotech investment event' because it brings together executives and investors into the one room for two intense days of presentations and networking.

Immuron's Chief Executive Office Mr Amos Meltzer's presentation focused on the Company's main value proposition being the Phase II NASH clinical trial due to commence last this year.

Following his presentation at the summit Mr Meltzer commented "that the summit was very well attended by approximately 150 persons including a mix of other biotech company management together with a large number of Australian, New Zealand and US fund managers, private investors, brokers and analysts.

It was a fantastic opportunity for Immuron to showcase the upcoming commencement of its fully funded Phase II NASH clinical trial which highlights another step in the unique opportunity Immuron now offers for investors".

Contacts:

Amos Meltzer, Chief Executive Officer
+61 (0)437 587 680

Investor Relations
Amanda Loh, Buchan Consulting
+61 (0)3 9866 4722

Websites: www.immuron.com and www.travelan.com

About Immuron

Immuron is a biopharmaceutical company focused on oral immunotherapy treatments using dairy-derived antibody products for humans. Immuron's technology platform products all have a very high safety profile. The company's current products and product candidates address infectious diseases of the gastrointestinal tract as well as chronic diseases. Immuron has an on-market product, Travelan®, for preventing travellers' diarrhoea. Immuron also has a phase 2 clinical product candidate for the treatment of inflamed fatty liver disease, known as Non-Alcoholic Steatohepatitis or NASH. Immuron's main scientific alliances are with Hadassah Medical Center (Israel) and Monash University (Australia).

The Immuron logo is located in the top right corner. It features the word "Immuron" in a blue, sans-serif font, with a stylized circular icon to the right of the text. The background of the entire slide is a blue-tinted anatomical illustration of a human torso, showing the internal organs including the liver, lungs, and intestines.

Immuron

NASH



JULY 2014

Amos Meltzer
Chief Executive Officer
Immuron Limited

Who am I


NASH

The Market

The Cause

Diagnosis &
Treatments

Immuron



Who am I





NASH

The Market

The Cause

Diagnosis &
Treatments

Immuron




An anatomical illustration of a human torso from the waist up, rendered in a semi-transparent blue style. The internal organs are visible, including the lungs, heart, liver, stomach, and intestines. The liver is highlighted in a bright red and yellow color, indicating its importance in the context of the image. The background is a solid blue gradient.

Immuron

WHAT IS NASH?

What is NASH? – a spectrum of conditions



Who am I

NASH

The Market

The Cause

Diagnosis &
Treatments


Immuron

There is also ASH: alcoholic steatohepatitis

My Doctor said “Only one glass of alcohol a day”



....I can live with that.

An anatomical illustration of a human torso from the waist up, rendered in a semi-transparent blue style. The internal organs are visible, including the lungs, heart, liver, stomach, and intestines. The liver is highlighted in a bright red and yellow color, indicating it is the focus of the image. The background is a solid blue gradient.

Immuron

HOW BIG IS THE
PROBLEM?

Who am I

NASH

The Market

The Cause

Diagnosis &
Treatments

Immuron

Metabolic Syndrome: *The Epidemic of the 21st Century*



Who am I

NASH


The Market

The Cause

Diagnosis &
Treatments

Immuron

The NASH Epidemic



Global Data, 2013

Who am I

NASH


The Market

The Cause

Diagnosis &
Treatments

Immuron

The NASH Epidemic



Deloitte Access Economics, 2013

Who am I

NASH


The Market

The Cause

Diagnosis &
Treatments

Immuron

The NASH Epidemic



Who am I

NASH

The Market

The Cause

Diagnosis &
Treatments

Immuron

The Market Opportunity



In 2012, **29.1M** Americans
(9.3%) had diabetes.
(American Diabetes Association)



By 2025, **25M** Americans
will have NASH.
(Centre for Disease Control)

Who am I

NASH

The Market

The Cause

Diagnosis &
Treatments


Immuron

The Market Opportunity



The demand for off-label pharmaceuticals for NASH is expected to grow to **US\$3.1 billion by 2016.**

(Global Data Forecast, 2011)

An anatomical illustration of a human torso from the waist up, rendered in a semi-transparent blue style. The internal organs are visible, including the lungs, heart, liver, stomach, and intestines. The liver is highlighted in a bright red and yellow color, indicating it is the focus of the image. The background is a solid blue color.

Immuron

WHAT CAUSES
NASH?

Who am I

NASH

The Market

The Cause

Diagnosis &
Treatments

Immuron

Pathogenesis of NASH

“Two Hits”

1. Oxidative Stress
2. Steatosis



Pathogenesis of NASH

1. Oxidative Stress

Disrupts cellular pathways

2. Steatosis


Abnormal retention of fat in cells

Obesity leads to chronic inflammation

Pathogenesis of NASH

Part of the Metabolic Syndrome

Inflammation



Pathogenesis of NASH



Inflammation


Strong evidence:

Endotoxin/LPS plays a role in activating inflammatory pathways associated with NASH.

Endotoxin drives NASH in a background of fatty liver.

"Leaky Gut"




An anatomical illustration of a human torso from the waist up, rendered in a semi-transparent blue style. The internal organs are visible, including the lungs, heart, liver, stomach, and intestines. The liver is highlighted in a bright red and yellow color, indicating its importance in the context of the image. The background is a solid blue color.

Immuron

HOW IS NASH
DIAGNOSED?

NASH Diagnosis Process



An anatomical illustration of a human torso from the waist up, rendered in a semi-transparent blue style. The internal organs are visible, including the lungs, heart, liver, stomach, and intestines. The liver is highlighted in a bright red and yellow color, indicating it is the focus of the image. The background is a solid blue gradient.

Immuron

CURRENT
TREATMENTS

Who am I

NASH

The Market

The Cause

Diagnosis &
Treatments

Immuron


Current Treatments Available for NASH?



None

Some Previous Attempts

Potential treatments previously trialled



An anatomical illustration of a human torso from the waist up, rendered in a semi-transparent blue style. The internal organs are visible, including the lungs, heart, liver, stomach, and intestines. The liver is highlighted in a bright red and yellow color, indicating it is the focus of the medical content. The background is a solid blue gradient.

Immuron

CURRENT
TREATMENTS
BEING DEVELOPED

Who am I

NASH

The Market

The Cause

Diagnosis &
Treatments

Immuron

The Competitive Landscape

Research Pre-clinical Phase I ← Phase II → Phase III Market

Company
Abbott
Shire
Gilead
Intercept
Galectin
Conatus
Galmed
Immuron
Genfit

Who am I

NASH

The Market

The Cause

Diagnosis &
Treatments

Immuron

The Competitive Landscape

Potential buyout opportunities



Company
Abbott
Shire
Gilead
↑ Big Small ↓
Intercept
Galectin
Conatus
Galmed
Immuron
Genfit

Who am I

NASH

The Market

The Cause

Diagnosis &
Treatments

Immuron

The Competitive Landscape

Bile Acid

Shire - LUM-002

Intercept - Obeticholic acid, modified bile acid

Galmed - Aramchol, Conjugate of Fatty acid and Fatty bile acid

Anti-fibrotic

Gilead - Simtuzumab, anti-fibrotic

Galectin – galectin proteins

Anti-Inflammatory + (anti-inflammatory, anti-diabetic, cholesterol control, FFA)

Immuron - Hyperimmune colostrum enriched with Anti-LPS Abs

Conatus – Emricassan, caspase protease inhibitor

Genfit - Peroxisome proliferator-activated receptor alpha

Who am I

NASH

The Market

The Cause

Diagnosis &
Treatments

Immuron

The Competitive Landscape

Company	Drug	Current Phase
Intercept	Obeticholic acid, modified bile acid	Phase II



CASE STUDY:

Intercept Pharmaceuticals
(NASDAQ: ICPT) \$1.5B before
more than quadrupling overnight
on successful NASH trial results

Who am I

NASH

The Market

The Cause

Diagnosis &
Treatments

Immuron


Pathogenesis of NASH




“Leaky Gut”

Antigen+adjuvant

Bacterial
antigens /
Endotoxin



**Systemic
chronic
inflammation**



Who am I

NASH


The Market

The Cause

Diagnosis &
Treatments

Immuron

Immuron's Solution for NASH



The background of the slide features a blue-tinted illustration of a human torso. The internal organs, including the lungs, liver, stomach, and a detailed view of the large and small intestines, are highlighted in a warm, glowing orange-red color. The Immuron logo is positioned in the upper right corner.

Immuron

THANK YOU

By Chief Executive Officer
Amos Meltzer
amos@immuron.com

OVERVIEW

What is NASH


NASH; Causes

PIPELINE



SUMMARY

Immuron

Fatty liver



Normal liver



© Deltagen Inc.